Table 2.
Evolution of visual acuity (VA). (A) Evolution of VA over time; (B) change in visual acuity after onset of intraocular inflammation.
| (A) | ||||||
| VA (ETDRS Letters) | n | Mean | SD | Median | IQR (25–75%) | Range |
| Baseline | 44 | 65.6 | 17.6 | 69.9 | 60–76 | 20–94 |
| Maximum | 17 | 67.6 | 15.3 | 73.9 | 59–79 | 35–85 |
| Last | 43 | 50.8 | 30.5 | 63.4 | 15–75 | 1–94 |
| (B) | ||||||
| n (Finding Reported) | % of Reported Eyes (n/N) | % of all Eyes (n = 41) * | ||||
| Visual loss >15 letters | 16 | 39.0 | 34.8 | |||
| Visual loss 6–15 letters | 6 | 14.6 | 13.0 | |||
| Stable vision (−5 to +5 letters) | 16 | 39.0 | 34.8 | |||
| Visual gain 6–15 letters | 3 | 7.3 | 6.5 | |||
n, number of observations; SD, standard deviation; IQR, interquartile range. Information about visual acuity at baseline was missing for two eyes. Maximum: maximum VA during brolucizumab treatment; * visual acuity was not reported for two eyes at baseline and for 3 at follow-up.